MedPageToday
MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in…
Read More
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC
Alejandro Culton
15:29
MedPage Today) — Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week non-anthracycline regimen in…